Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000938
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 13
---
- |

(x) “” means, with respect to any Fixed Purchase, VWAP Purchase or Additional VWAP Purchase made pursuant to
hereof, $1.00, which shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, share split, reverse
share split, Depositary Share-Ordinary Share ratio change or other similar transaction and, effective upon the consummation of any such
reorganization, recapitalization, non-cash dividend, share split, reverse share split, Depositary Share-Ordinary Share ratio change or
other similar transaction, the Floor Price shall mean the lower of (i) the adjusted price and (ii) $1.00.

(y) “” means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of
operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than any material adverse
effect that resulted primarily from (A) any change in the United States or foreign economies or securities or financial markets in general
that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B) any change that generally affects
the industry in which the Company and its Subsidiaries operate that does not have a disproportionate effect on the Company and its Subsidiaries,
taken as a whole, (C) any change arising in connection with pandemics, earthquakes, hostilities, acts of war, sabotage or terrorism or
military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions,
(D) any action taken, or omitted to be taken, by the Investor, its affiliates or its or their respective successors and assigns with respect
to the transactions contemplated by this Agreement or the Registration Rights Agreement, (E) the effect of any change in applicable laws
or accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, or (F) any change
resulting from compliance with terms of this Agreement or the Registration Rights Agreement or the consummation of the transactions contemplated
by this Agreement and the Registration Rights Agreement, or (iii) the Company’s ability to perform in any material respect on a
timely basis its obligations under any Transaction Document to be performed as of the date of determination.

(z) “” means the first day of the month immediately following